









Clumps of Mesenchymal Stem Cell/Extracellular 
Matrix Complexes Generated with Xeno-Free 
Conditions Facilitate Bone Regeneration via Direct 
and Indirect Osteogenesis. 
 
(ࢮࣀࣇ࣮ࣜ᮲௳ୗ࡟స〇ࡋࡓ㛫ⴥ⣔ᖿ⣽⬊㞟ሢ Clumps of mesenchymal 
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ᢚไࡍࡿࡇ࡜࡟ࡼࡗ࡚ෆᅾᛶࡢ⣽⬊ࡢ㐟㉮ࢆຓࡅࠊ෌⏕ࡢ㊊ሙࢆᥦ౪ࡍࡿ Guided Tissue 
Regeneration (GTR) ἲ [8] ࡀᗈࡃ⮫ᗋᛂ⏝ࡉࢀ࡚࠸ࡿࠋࡲࡓࠊࢧ࢖ࢺ࢝࢖ࣥࢆ⏝࠸ࡓṑ࿘
⤌⧊෌⏕⒪ἲ࡜ࡋ࡚ basic fibroblast growth factor (bFGF) [9, 10]ࠊplatelet derived growth 
factor (PDGF) [11-13]ࠊbone morphogenetic protein (BMP) [14, 15] ࡀ⮫ᗋᛂ⏝ࡉࢀ࡚࠸
ࡿࠋࡉࡽ࡟ࠊinsulin-like growth factor-I (IGF-I) [9]ࠊtransforming growth factor-β (TGF-














ᖿ⣽⬊ࡀ㐺ࡋ࡚࠸ࡿ࡜⪃࠼ࡽࢀࡿࠋᖿ⣽⬊࡜ࡋ࡚ࠊ⬇ᛶᖿ⣽⬊ (embryonic stem cells: ES





ࢀ࡚࠸ࡿࠋ≉࡟㛫ⴥ⣔ᖿ⣽⬊ (mesenchymal stem cells: MSCs) ࡣ㦵ࠊ㌾㦵ࠊ➽⤌⧊ࠊ⥺
⥔ࠊ⭝ࠊ⬡⫫⤌⧊࡞࡝ࡢ㛫ⴥ⤌⧊ࡸ⚄⤒⣽⬊࡟ศ໬ࡍࡿࡇ࡜ࡀሗ࿌ࡉࢀ࡚࠾ࡾ [22]ࠊ⌧᫬
Ⅼ࡟࠾࠸࡚⣽⬊἞⒪ࡢ⣽⬊※࡜ࡋ࡚᭷ᮃどࡉࢀ࡚࠸ࡿࠋ≉࡟ࠊ㦵㧊⏤᮶㛫ⴥ⣔ᖿ⣽⬊ (bone 
marrow mesenchymal stem cells: BMMSCs) ࡣ⮫ᗋ࡟࠾࠸࡚ࡶከࡃ౑⏝ࡉࢀ࡚࠸ࡿ [23]ࠋ 
ࡇࢀࡲ࡛ࡢᇶ♏◊✲࡛ࠊ㦵㧊⏤᮶ࡢ MSCs ࢆ࢔ࢸࣟࢥ࣮ࣛࢤࣥࢤࣝ࡜ΰ࿴ࡋ࡚ࣅ࣮ࢢࣝ




fluorescent protein (GFP) ࢆ㑇ఏᏊᑟධࡋࡓMSCsࢆ⛣᳜ࡋࡓ࡜ࡇࢁࠊ⛣᳜ᚋ 4㐌┠࡟࠾
࠸࡚෌⏕ࡉࢀࡓṑ࿘⤌⧊ࡢᵓᡂ⣽⬊ࠊࡍ࡞ࢃࡕࢭ࣓ࣥࢺⱆ⣽⬊ࠊ㦵ⱆ⣽⬊ࠊ㦵⣽⬊ࠊṑ࿘㠌
ᖏ୰ࡢ⥺⥔ⱆ⣽⬊ࡀ GFP 㝧ᛶࢆ♧ࡋࡓ [25]ࠋࡇࡢ⤖ᯝ࠿ࡽࠊ⛣᳜ࡉࢀࡓ MSCs ࡀ⛣᳜㒊
఩ᒁᡤ࡛ቑṪ࣭ศ໬ࡍࡿࡇ࡜࡛ṑ࿘⤌⧊෌⏕࡟㛵୚ࡍࡿࡇ࡜ࡀ♧၀ࡉࢀࡓࠋ 






















࡛ MSCs ࡢ㦵⤌⧊෌⏕ᶵᗎ࡜ࡋ࡚ࠊ⛣᳜ඛ࡛ࢻࢼ࣮⣽⬊⮬㌟ࡀ㦵ศ໬ࡍࡿ┤᥋ⓗ㦵ᙧᡂ 

























➨ 2❶ Xeno-free/Serum-free᮲௳ୗ࡛స〇ࡋࡓ C-MSCsࡢᛶ㉁ 
 
➨ 1⠇ Xeno-free/Serum-free᮲௳ୗ࡛ࡢ C-MSCsస〇 
 
➨ 1㡯 ᴫ せ 
In vitro࡟࠾࠸࡚ࣄࢺ㦵㧊⏤᮶MSCs࠿ࡽ Xeno-free/Serum-free᮲௳ୗ࡟ C-MSCsࢆ
స〇ࡋࠊࡑࡢ⏕≀Ꮫⓗᛶ㉁ࢆ᳨ウࡋࡓࠋ 
 
➨ 2㡯 ᮦᩱ࡜᪉ἲ 
1. ࣄࢺMSCsࡢᇵ㣴ἲ 
⣽⬊ࡣᗈᓥ኱Ꮫ೔⌮ጤဨ఍࡛ᢎㄆࢆᚓࡓୖ࡛ࠊ⌮໬Ꮫ◊✲ᡤ㸦Ⲉᇛ㸧࠿ࡽᥦ౪ࡉࢀࡓࣄࢺ
⭠㦵⏤᮶ࡢ  MSCs (MSCs-R41) ࢆ౑⏝ࡋࡓࠋᇵ㣴ᾮࡣࠊDulbecco’s Modified Eagle’s 
Medium (DMEM) (Sigma-Aldrich, Steinheim, Germany) ࡟ 10% fetal bovine serum 
(FBS) (Hyclone, Logan, UT, USA)ࠊ100 U/ml penicillin (Sigma-Aldrich)ࠊ100 μg/ml 
streptomycin (Sigma-Aldrich) ࢆῧຍࡋࡓࡶࡢࢆ౑⏝ࡋࡓࠋᇵ㣴ࡣ 10 cm ࢩ࣮ࣕࣞ
㸦Corning, Corning, NY, USA㸧ୖ࡛ࠊ37Υࠊ5㸣 CO2Ẽ┦ୗ࡟⣽⬊ࡀࢧࣈࢥࣥࣇ࢚ࣝࣥ
ࢺ࡟࡞ࡿࡲ࡛⾜ࡗࡓࠋᇵᆅ஺᥮ࡣ 3᪥ẖ࡟⾜ࡗࡓࠋᐇ㦂࡟ࡣ 4௦⥅௦ࡋࡓMSCsࢆ⏝࠸ࡓࠋ 
 
2. Xeno-free/Serum-free ᮲௳ୗ࡛ࡢ⣽⬊㞟ሢ C-MSCsࡢస〇ἲ 
Xeno-free/Serum-free᮲௳ୗ࡟ C-MSCsࢆస〇ࡍࡿࡓࡵࠊMSCsࢆ 48-wellࣉ࣮ࣞࢺ࡟
1.0×105 cells/well࡛᧛✀ࡋࠊXeno-freeቑṪᇵᆅ (Prime-XV MSC expansion XSFM, Irvine 
Scientific, Santa Ana, CA, USA) ࡛ 4᪥㛫ᇵ㣴ࡋ ECMࢆ⏘⏕ࡉࡏࡓࠋࡑࡢᚋࠊ࢙࢘ࣝ࠿
ࡽ MSCs/ECM 」ྜయࢆ㕌ⓗ࡟๤㞳ࡋ࡚ᾋ㐟ࡉࡏࠊ24-well ultra low binding ࣉ࣮ࣞࢺ 
(AGC ࢸࢡࣀࢢࣛࢫࠊ㟼ᒸ ) ࡟⛣ືࡋࠊࡉࡽ࡟ Xeno-free 㦵ศ໬ㄏᑟᇵᆅ  (MSCgo 
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Osteogenic-SF, XF medium, Biological Industries, Beit Haemek, Israel) ࡟࡚⌫≧࡟࡞ࡿ
ࡲ࡛ 3᪥㛫ᇵ㣴ࡍࡿࡇ࡜࡛⣽⬊㞟ሢ C-MSCsࢆᚓࡓࠋMSCs/ECM 」ྜయࢆ๤㞳ࡋࡓ᪥ࢆ
Day0 (⣽⬊ࢩ࣮ࢺ)ࠊ๤㞳 1᪥ᚋࢆ Day1ࠊ๤㞳 3᪥ᚋࢆ Day3 (C-MSCs) ࡜ࡋࠊྛ᫬Ⅼ࡛
⣽⬊㞟ሢ࡜ࡋ࡚ᅇ཰ࡋࠊゎᯒࢆ⾜ࡗࡓࠋ 
 
3. ࣇ࣮ࣟࢧ࢖ࢺ࣓ࢺ࣮ࣜ (FCM) ゎᯒ 
  Day0 (⣽⬊ࢩ࣮ࢺ) ࡢMSCs/ECM」ྜయ࡟ࠊ37Υ࡛ 20ศ㛫 accutase (Innovative Cell 
Technologies, San Diego, CA, USA) ฎ⌮ࢆ᪋ࡋࠊࢧࣥࣉࣝࡢᅇ཰ࢆ⾜ࡗࡓࠋ⣽⬊ΰ⃮ᾮࢆ
ᚓࡿࡓࡵ࡟ࠊᅇ཰ࡋࡓࢧࣥࣉࣝࢆ 70 μm ࢭࣝࢫࢺ࣮ࣞࢼ࣮ (BD Biosciences, Franklin 
Lakes, NJ, USA) ࡛ℐ㐣ࡋࡓࠋ1% FBS (Hyclone, Logan) /PBS⁐ᾮ࡛ 1᫬㛫ࣈࣟࢵ࢟ࣥ
ࢢࡋࠊPBS࡛Ὑίᚋࠊᚓࡽࢀࡓ⣽⬊࡟ᢠయࢆ 4Υ࡛ 1᫬㛫཯ᛂࡉࡏࡓࠋᢠయ࡜ࡋ࡚ PEᶆ㆑
ᢠࣄࢺ CD105࣐࢘ࢫࣔࣀࢡ࣮ࣟࢼࣝᢠయ (SN6; 1:100; eBioscience, San Diego, CA, USA)ࠊ
PEᶆ㆑ᢠࣄࢺ CD90࣐࢘ࢫࣔࣀࢡ࣮ࣟࢼࣝᢠయ (5E10; 1:100; BD pharmingen, Franklin 
lakes, NJ, USA)ࠊPE ᶆ㆑ᢠࣄࢺ CD73 ࣐࢘ࢫࣔࣀࢡ࣮ࣟࢼࣝᢠయ (AD2; 1:100; BD 
pharmingen)ࠊPE ᶆ㆑ᢠࣄࢺ CD45 ࣐࢘ࢫࣔࣀࢡ࣮ࣟࢼࣝᢠయ  (HI30; 1:100; BD 
pharmingen)ࠊPE ᶆ㆑ᢠࣄࢺ CD34 ࣐࢘ࢫࣔࣀࢡ࣮ࣟࢼࣝᢠయ  (563; 1:100; BD 
pharmingen) ࠾ࡼࡧ PE ᶆ㆑࢔࢖ࢯࢱ࢖ࣉ࣭ࢥࣥࢺ࣮ࣟࣝᢠయ (MOPC-21; 1:100; BD 
pharmingen) ࢆ཯ᛂࡉࡏࡓࠋPBS࡛ὙίᚋࠊFACScan flow cytometer (BD Biosciences) 
࡜ Cell Quest software (BD Biosciences) ࢆ⏝࠸࡚ゎᯒࢆ⾜ࡗࡓࠋ 
 
4. ⤌⧊Ꮫⓗゎᯒ 
1) ࣐࣊ࢺ࢟ࢩ࣭࢚ࣜࣥ࢜ࢪࣥ (HE) ᰁⰍ 




ᰁⰍࢆ⾜࠸ࠊගᏛ㢧ᚤ㙾㸦ECLIPSE E600W; ࢽࢥࣥࠊᮾி㸧࡛ほᐹࡋࡓࠋ 
 
2) ⺯ගච␿ᰁⰍ 
 Day 3࡛ C-MSCsࢆᅇ཰ࡋࠊ4 % ࣃ࣒ࣛ࣍ࣝ࢔ࣝࢹࣄࢻ⁐ᾮ࡛ᅛᐃࡋࡓᚋࠊ30㸣 ࢫࢡ
࣮ࣟࢫ⁐ᾮ࡛⨨᥮ࡋࡓࠋC-MSCsࢆ OCT ࢥࣥࣃ࢘ࣥࢻ (Sakura Finetek USA, Torrance, 
CA, USA) ࡟ໟᇙᚋࠊࢡࣛ࢖࢜ࢫࢱࢵࢺࢆ⏝࠸࡚ཌࡉ 20 μm࡛ⷧษࡋ෾⤖ษ∦ࢆస〇ࡋ
ࡓࠋษ∦ࢆ 1᫬㛫㢼஝ࡉࡏࠊPBS࡛Ὑίᚋࠊ0.5% TRITON X-100 (Sigma-Aldrich) /PBS 
⁐ᾮࢆ⏝࠸࡚㏱㐣໬ࡋࡓࠋPBS࡛Ὑίࡋࠊ5% BSA/0.1% TWEEN 20/PBS ⁐ᾮࢆ⏝࠸࡚
ᐊ ࡛ 1᫬㛫ࣈࣟࢵ࢟ࣥࢢࡋࡓࠋษ∦ࢆ PBS࡛Ὑίᚋࠊ୍ḟᢠయࢆ 4Υ୍࡛᫨ኪ཯ᛂࡉࡏ
ࡓࠋ୍ḟᢠయ࡜ࡋ࡚ࠊᢠࣄࢺϨᆺࢥ࣮ࣛࢤࣥ (ࣄࢺ COLϨ) ࣛࣅࢵࢺࣔࣀࢡ࣮ࣟࢼࣝᢠయ 
(EPR7785; 1:100; abcam, Cambridge, UK)ࠊᢠࣄࢺ࢜ࢫࢸ࣏࢜ࣥࢳࣥ (ࣄࢺ OPN) ࣖࢠ
࣏ࣜࢡ࣮ࣟࢼࣝᢠయ (1:100; R&D Systems, Minneapolis, MN, USA)ࠊᢠࣄࢺ࢜ࢫࢸ࢜࢝
ࣝࢩࣥ (ࣄࢺ OCN) ࣐࢘ࢫࣔࣀࢡ࣮ࣟࢼࣝᢠయ (OCG3; 1:100; abcam, Cambridge, UK) 
ࢆ཯ᛂࡉࡏࡓࠋ཯ᛂ⤊஢ᚋࠊษ∦ࢆ PBS࡛Ὑίࡋࠊ஧ḟᢠయࢆᐊ ࡛ 5᫬㛫཯ᛂࡉࡏ
ࡓࠋ஧ḟᢠయ࡜ࡋ࡚ࠊAlexa Fluor 488 ᢠࣛࣅࢵࢺ IgGᢠయ (1:100; ThermoFisher, 
Waltham, MA, USA)ࠊAlexa Fluor 594 ᢠ࣐࢘ࢫ IgGᢠయ (1:100; ThermoFisher) ࡲࡓ
ࡣ Alexa Fluor 594 ᢠࣖࢠ IgGᢠయ (1:100; ThermoFisher) ࢆ཯ᛂࡉࡏࡓࠋ཯ᛂ⤊஢
ᚋࠊษ∦ࢆ PBS࡛Ὑίࡋࠊ⣽⬊᰾ࢆ 4’,6-diamidino-2-phenylindole (DAPI) solution 
(1:200; ྠோ໬Ꮫ◊✲ᡤࠊ⇃ᮏ) ࢆ⏝࠸࡚ᑐẚᰁⰍࡋࡓࠋ཯ᛂ⤊஢ᚋࠊษ∦ࢆ PBS ࡛Ὑί
ࡋࠊỈ⣔ᑒධ๣ (Fluoromount-G; Thermo Fisher) ࢆ⏝࠸࡚ᑒධࡋࡓࠋྛࢱࣥࣃࢡⓎ⌧ཬ
ࡧ⣽⬊᰾ࢆඹ↔Ⅼ࣮ࣞࢨ࣮㢧ᚤ㙾 (Olympus FV1000D laser scanning confocal 






 Day 3࡛ C-MSCsࢆᅇ཰ࡋࠊ4 % ࣃ࣒ࣛ࣍ࣝ࢔ࣝࢹࣄࢻ⁐ᾮ࡛ᅛᐃࡋࡓࠋヨᩱࢆࣃࣛࣇ
࢕ࣥ࡟ໟᇙࡋࠊ20 μmࡢཌࡉ࡛ⷧษࡋࡓࠋࣃࣛࣇ࢕ࣥษ∦ࢆ⬺ࣃࣛࣇ࢕ࣥᚋࠊDeadEnd™ 
Fluorometric TUNEL System (Promega, Madison, WI, USA) ࢆ⏝࠸࡚࢔࣏ࢺ࣮ࢩࢫ⣽⬊
ࢆ᳨ฟࡋࡓࠋ⣽⬊᰾ࢆ DAPI solution (1:200; ྠோ໬Ꮫ◊✲ᡤ) ࢆ⏝࠸࡚ᑐẚᰁⰍࡋࡓࠋ
཯ᛂ⤊஢ᚋࠊษ∦ࢆ PBS࡛ὙίࡋࠊỈ⣔ᑒධ๣ (Fluoromount-G; Thermo Fisher) ࢆ⏝
࠸࡚ᑒධࡋࡓࠋ࢔࣏ࢺ࣮ࢩࢫ⣽⬊ཬࡧ⣽⬊᰾ࡣඹ↔Ⅼ࣮ࣞࢨ࣮㢧ᚤ㙾 (Olympus 
FV1000D laser scanning confocal microscope; ࢜ࣜࣥࣃࢫ) ࢆ⏝࠸࡚ほᐹࡋࡓࠋ 
 
➨ 3㡯  ⤖ ᯝ 
➨ 2❶ ➨ 2㡯࡟グ㍕ࡋࡓ᪉ἲ࡛ Xeno-free᮲௳ୗ࡟ C-MSCsࢆస〇ࡋࡓࠋMSCs/ECM
」ྜయࢆᚓࡿࡓࡵ࡟ࠊMSCsࢆ Prime-XV MSC expansion XSFM࡛ 4᪥㛫ᇵ㣴ࡋࡓᚋࠊ
㕌ⓗ࡟๤㞳ࡋࡓ (ᅗ 1A-a)ࠋ࢙࢘ࣝ࠿ࡽ⣽⬊ࢩ࣮ࢺࡢ≧ែ࡛๤㞳ࡋࡓ MSCs/ECM」ྜయ
ࢆMSCgo Osteogenic-SF, XF medium ࡟࡚⌫≧࡟࡞ࡿࡲ࡛ 3 ᪥㛫ᇵ㣴ࡋࡓ࡜ࡇࢁࠊ⣽⬊
㞟ሢ C-MSCsࢆᚓࡿࡇ࡜ࡀ࡛ࡁࡓ (ᅗ 1A-b)ࠋXeno-free᮲௳ୗ࡛ࡢᇵ㣴ࡀMSCsࡢᛶ㉁
࡟ᙳ㡪ࢆ୚࠼ࡿ࠿ࢆ☜ㄆࡍࡿࡓࡵ࡟ࠊFCMゎᯒ࡟ࡼࡗ࡚MSC࣐࣮࣮࢝ࡢⓎ⌧⋡ࢆホ౯ࡋ
ࡓ࡜ࡇࢁࠊMSC㝧ᛶ࣐࣮࣮࡛࢝࠶ࡿ CD105ࠊCD90ࠊCD73ࡣ࠸ࡎࢀࡶ 93㸣௨ୖࡢ㧗࠸










ࣥࣃࢡ࡛࠶ࡿࣄࢺ OPN࡜ࣄࢺ OCNࡢⓎ⌧ࡣ☜ㄆࡉࢀ࡞࠿ࡗࡓ (ᅗ 1E)ࠋ 
 
➨ 2⠇ Xeno-free/Serum-free᮲௳ୗ࡛స〇ࡋࡓ C-MSCsࡢ㦵⤌⧊෌⏕⬟ࡢ᳨ウ 
 
➨ 1㡯 ᴫ せ 
Xeno-free/Serum-free᮲௳ୗ࡛స〇ࡋࡓ C-MSCsࢆ NOD/ShiJic-scidJcl (SCID) ࣐࢘
ࢫࡢ㢌⵹ෙ㦵Ḟᦆ࡟⛣᳜ࡋࠊ㦵⤌⧊෌⏕⬟ࡢ᳨ウࢆ⾜ࡗࡓࠋ 
 
➨ 2㡯 ᮦᩱ࡜᪉ἲ 
1. SCID࣐࢘ࢫ㢌⵹ෙ 1.6mm㦵Ḟᦆࣔࢹࣝ࡬ࡢ C-MSCs⛣᳜ 
 ᐇ㦂࡟ࡣࠊච␿୙඲ࣔࢹࣝື≀ࡢ㞝ࡢ SCID ࣐࢘ࢫ  (7–8 㐌㱋 , Charles River 




ࣝࣇ࢓ࣀ࣮ࣝ (࣋ࢺࣝࣇ࢓࣮ࣝࠊ5mg/kg) ࢆ⏝࠸ࡓࠋ㢌㡬㒊ࢆ๋ẟࠊᾘẘᚋ࡟ 15c␒ࡢ࣓ࢫ
ࢆ⏝࠸࡚ᚋ㢌㦵࠿ࡽ๓㢌㦵ࡲ࡛ࡢ⓶⭵ࢆ▮≧ษ㛤ࡋࡓࠋ⓶⭵ࢆ㦵⭷ࡈ࡜๤㞳ࡋࠊ㢌⵹㦵ࢆ᫂
♧ࡋࡓࠋᕥྑࡢ㢌㡬㦵࡟ࣛ࢘ࣥࢻࣂ࣮ࢆ⏝࠸࡚ࠊ㢌⵹⦭ྜࢆ㑊ࡅࡿࡼ࠺࡟┤ᚄ 1.6 mm ࡢ
㦵Ḟᦆࢆస〇ࠊ⛣᳜ᗋ࡜ࡋࡓࠋ㦵Ḟᦆ࡟ᑐࡋ࡚ C-MSCs ࢆ 1ࡘ⛣᳜ࡋࠊ4-0⤱⣒࡛⦭ྜࡋ
ࡓࠋ࡞࠾ࠊ㦵Ḟᦆ࡟ఱࡶ⛣᳜ࡋ࡞࠿ࡗࡓ⩌ࢆ㠀⛣᳜⩌࡜ࡋࡓࠋ 
 
2. micro CT ゎᯒἲ  
⣽⬊⛣᳜ᚋ 1, 2, 4, 8 㐌┠࡛࣐࢘ࢫࢆᒕẅࡋࠊ㢌⵹㦵ࢆᅇ཰ᚋ ࡟ 4 % ࣃ࣒ࣛ࣍ࣝ࢔ࣝࢹ
16 
 
ࣄࢻ⁐ᾮ࡛ᅛᐃࡋࡓࠋࢧࣥࣉࣝࢆPBS࡛Ὑίᚋࠊmicro CT (Skyscan 1176㸪Bruker, Billerica, 
MA, USA) ࡛᧜ᙳࡋࡓࠋ᧜ᙳ᮲௳ࡣࠊ⟶㟁ᅽ 50 kVࠊ⟶㟁ὶ 0.5 mAࠊࣆࢡࢭࣝࢧ࢖ࢬ 8 
μmࠊࢫࢸࢵࣉゅᗘ 0.5 ᗘࠊ㟢ග᫬㛫 230 ms࡛⾜ࡗࡓࠋCTVOL software 2.3.2.0 (64bit) 
(Bruker) ࢆ⏝࠸࡚⏬ീ෌ᵓᡂࢆ⾜ࡗࡓࠋ㦵Ḟᦆ㒊ࢆྵࡴࡼ࠺࡟ࠊ┤ᚄ 1.6 mmࡢ෇ᙧ600 
μm (33ࢫࣛ࢖ࢫ) ࡢ෇ᰕ≧㛵ᚰ㡿ᇦ (ROI) ࢆタᐃࡋࠊCT-An software 1.12.0.0+ (Bruker) 
ࢆ⏝࠸࡚ࠊThreshold 80-255ࡢ⠊ᅖ࡛ゎᯒࢆ⾜ࡗࡓ [36]ࠋ 
 
3. HEᰁⰍ 






Studentࡢ t᳨ᐃࢆ⏝࠸࡚ 2⩌㛫ࡢᕪࡢ⤫ィゎᯒࢆ⾜ࡗࡓࠋ 
 
➨ 3㡯 ⤖ ᯝ 
micro CT (๓㢌᩿༢ᒙཬࡧỈᖹ᩿ 3Dᵓ⠏⏬ീ) ᧜ᙳࢆ⾜ࡗࡓ࡜ࡇࢁࠊ㠀⛣᳜⩌࡛ࡣࠊ㢌
⵹ෙḞᦆస〇8㐌㛫ᚋࡲ࡛ࠊḞᦆ㒊࡟▼⅊໬≀ࡢᙧᡂࡣ࡯࡜ࢇ࡝ほᐹࡉࢀ࡞࠿ࡗࡓ (ᅗ2B)ࠋ
ࡇࡢᡤぢ࡜୍⮴ࡋ࡚ࠊHEᰁⰍീ࡛ࡣࠊࡑࡢḞᦆ㒊࡟ⷧ࠸⥺⥔ᛶ⤌⧊ࡀㄆࡵࡽࢀࡿࡢࡳ࡛࠶
ࡗࡓ (ᅗ 2D)୍ࠋ ᪉࡛ࠊC-MSCs⛣᳜⩌࡛ࡣ᫬㛫౫Ꮡⓗ࡟Ḟᦆ㒊࡟᫂ࡽ࠿࡞▼⅊໬≀ࡢᙧᡂ
ࢆㄆࡵࡓ (ᅗ 2B, C)ࠋHEᰁⰍീ࡛ࡣࠊ⛣᳜ 1㐌ᚋ࡛ࡣḞᦆ㒊࡟ࠊ⛣᳜ࡋࡓ C-MSCs⏤᮶
࡜ᛮࢃࢀࡿከࡃࡢ⣽⬊࡜⥺⥔ᛶࡢᇶ㉁ᵓ㐀ࢆ☜ㄆࡋࡓ (ᅗ 2E)ࠋ⛣᳜ 2 㐌ᚋ࡛ࡣᇶ㉁ᵓ㐀






ࡓ (ᅗ 2E)ࠋ 
 
➨ 3⠇ ᑠ ᣓ 





















➨ 3❶ C-MSCsࡢ㦵⤌⧊෌⏕ᶵᗎࡢゎᯒ 
 
➨ 1⠇ C-MSCs⛣᳜࡟ࡼࡿ㦵⤌⧊෌⏕㐣⛬࡟࠾ࡅࡿࢻࢼ࣮⣽⬊࡜࣍ࢫࢺ⣽⬊ࡢศᕸゎᯒ 
 





➨ 2㡯 ᮦᩱ࡜᪉ἲ 
1. ࣄࢺ vimentin ࡟ᑐࡍࡿ⺯ගච␿ᰁⰍἲ 
 ➨ 2❶ ➨ 2⠇ ➨ 2㡯 3. ࡛グ㍕ࡋࡓ᪉ἲ࡟ᚑ࠸ࠊ⛣᳜ᚋ 1, 2, 4, 8 㐌┠ࡢ㢌⵹㦵ࡢࣃ
ࣛࣇ࢕ࣥໟᇙࢆ⾜࠸ࠊࡑࡢᚋࠊ๓㢌᩿᪉ྥ࡟ 20 μmࡢཌࡉ࡛ⷧษࡋࡓࠋࣃࣛࣇ࢕ࣥษ∦ࢆ
PBS࡛Ὑίᚋࠊ5% BSA/0.1% TWEEN 20/PBS ⁐ᾮࢆ⏝࠸࡚ᐊ ࡛ 1᫬㛫ࣈࣟࢵ࢟ࣥࢢ
ࡋࡓࠋษ∦ࢆ PBS࡛Ὑίᚋࠊ୍ḟᢠయ࡜ࡋ࡚ࠊᢠࣄࢺ vimentin ࣛࣅࢵࢺࣔࣀࢡ࣮ࣟࢼࣝ
ᢠయ (SP20; 1:100; abcam) ࢆ 4Υ୍࡛᫨ኪ཯ᛂࡉࡏࡓࠋ཯ᛂ⤊஢ᚋࠊษ∦ࢆ PBS࡛Ὑί
ࡋࠊ஧ḟᢠయ࡜ࡋ࡚ Alexa Fluor 488 ᢠࣛࣅࢵࢺ IgGᢠయ (1:100; ThermoFisher) ࢆᐊ
 ࡛ 5᫬㛫཯ᛂࡉࡏࡓࠋ཯ᛂ⤊஢ᚋࠊษ∦ࢆ PBS࡛Ὑίࡋࠊ⣽⬊᰾ࢆ DAPI solution 
(1:200; ྠோ໬Ꮫ◊✲ᡤ) ࢆ⏝࠸࡚ᑐẚᰁⰍࡋࡓࠋ཯ᛂ⤊஢ᚋࠊษ∦ࢆ PBS࡛ὙίࡋࠊỈ
⣔ᑒධ๣ (Fluoromount-G; Thermo Fisher) ࢆ⏝࠸࡚ᑒධࡋࡓࠋࢧࣥࣉࣝࡢ⺯ගࢩࢢࢼࣝ
ࢆඹ↔Ⅼ࣮ࣞࢨ࣮㢧ᚤ㙾(Olympus FV1000D laser scanning confocal microscope; ࢜ࣜࣥ







  ➨ 2❶ ➨ 2⠇ ➨ 2㡯 4. ࡟グ㍕ࡋࡓ᪉ἲ࡛⾜ࡗࡓࠋ 
 
➨ 3㡯 ⤖ ᯝ 
 ⛣᳜ 1 㐌┠࡛ࡣࠊḞᦆ㒊ࡣ⛣᳜ࡋࡓ C-MSCs ⏤᮶࡛࠶ࡿࡇ࡜ࢆ♧ࡍࣄࢺ vimentin 㝧ᛶ
ࡢࢻࢼ࣮⣽⬊࡛‶ࡓࡉࢀ࡚࠸ࡓ (ᅗ 3A)ࠋࡑࡢᚋࠊ᫬㛫⤒㐣౫Ꮡⓗ࡟ࢻࢼ࣮⣽⬊ᩘࡣῶᑡࡋ
ࡓࡀࠊ⛣᳜ 4 㐌㛫ࡲࡓࡣ 8 㐌㛫ᚋ࡟Ḟᦆ୰ኸ㒊࡟ᙧᡂࡉࢀࡓ㦵ᵝ⤌⧊ෆ㒊ࡢ⣽⬊ࡣࣄࢺ
vimentin 㝧ᛶࢆ♧ࡋࡓࡇ࡜࠿ࡽࠊ⛣᳜ࡋࡓࢻࢼ࣮⣽⬊ࡣ㦵ᙧᡂ⣽⬊࡟ศ໬ࡋ࡚࠸ࡿྍ⬟ᛶ




➨ 2⠇ ᪂⏕㦵ᵝ⤌⧊ࡢ㦵㉁ࡢゎᯒ 
 





➨ 2㡯 ᮦᩱ࡜᪉ἲ 
1. AzanᰁⰍἲ 
➨ 2❶ ➨ 2⠇ ➨ 2㡯 3. ࡛グ㍕ࡋࡓ᪉ἲ࡟ᚑ࠸ࠊ⛣᳜ᚋ 1, 2, 4, 8 㐌┠ࡢ㢌⵹㦵ࡢࣃ
ࣛࣇ࢕ࣥໟᇙࢆ⾜࠸ࠊࡑࡢᚋࠊ๓㢌᩿᪉ྥ࡟ 8 μmࡢཌࡉ࡛ⷧษࡋࡓࠋ⬺ࣃࣛࣇ࢕ࣥᚋࠊ
10% ࢺࣜࢡࣟࣟ㓑㓟࣭㔜ࢡ࣒ࣟ㓟࢝ࣜ࢘ ࣒ΰྜᾮ (ࢼ࢝ࣛ࢖ࢸࢫࢡࠊி㒔) ࡛ 8ศ㛫๓
20 
 
ฎ⌮ࡋࡓᚋࠊ࢔ࢰ࣑࢝ࣥ G (ࢼ࢝ࣛ࢖ࢸࢫࢡ) ࡛ 30ศ㛫ᰁⰍࡋࡓࠋษ∦ࢆ࢔ࢽ࢚ࣜࣥࢱࣀ
࣮ࣝ࡜ 1% 㓑㓟࢚ࢱࣀ࣮࡛ࣝὙίࡋࡓᚋࠊ 5% ࣜࣥࢱࣥࢢࢫࢸࣥ㓟Ỉ⁐ᾮ (ࢼ࢝ࣛ࢖ࢸࢫ






➨2⠇ ➨2㡯 3. ࡛グ㍕ࡋࡓ᪉ἲ࡟ᚑ࠸ࠊ⛣᳜ᚋ1, 2, 4, 8 㐌┠ࡢ㢌⵹㦵ࡢࣃࣛࣇ࢕ࣥໟᇙ
ࢆ⾜࠸ࠊࡑࡢᚋࠊ๓㢌᩿᪉ྥ࡟20 μmࡢཌࡉ࡛ⷧษࡋࡓࠋPBS࡛ὙίᚋࠊLAB solution 
(Polyscience, Warrington, PA, USA) ࢆ⏝࠸࡚ᐊ ࡛15ศ㛫ฎ⌮ࡋࠊᢠཎ㈿ά໬ࢆ⾜ࡗ
ࡓࠋษ∦ࢆPBS࡛Ὑίᚋࠊ5% BSA/0.1% Tween 20/PBS⁐ᾮࢆ⏝࠸࡚ᐊ ࡛1᫬㛫ࣈࣟࢵ
࢟ࣥࢢࡋࡓࠋࣄࢺOCNࡢᰁⰍ࡛ࡣࠊࣈࣟࢵ࢟ࣥࢢࡢ┤๓࡟Mouse on Mouse blocking 
reagent (Vector Laboratories, Burlingame, CA, USA) ࢆ⏝࠸࡚ᐊ ࡛1᫬㛫๓ฎ⌮ࢆ⾜
ࡗࡓࠋษ∦ࢆPBS࡛Ὑίᚋࠊ୍ḟᢠయࢆ4Υ୍࡛᫨ኪ཯ᛂࡉࡏࡓࠋ୍ḟᢠయ࡜ࡋ࡚ࠊᢠࣄ
ࢺCOLϨ ࣛࣅࢵࢺࣔࣀࢡ࣮ࣟࢼࣝᢠయ (EPR7785; 1:100; abcam)ࠊᢠࣄࢺOPN ࣖࢠ࣏
ࣜࢡ࣮ࣟࢼࣝᢠయ (1:100; R&D Systems)ࠊᢠࣄࢺOCN ࣐࢘ࢫࣔࣀࢡ࣮ࣟࢼࣝᢠయ 
(OCG3; 1:100; abcam) ࢆ཯ᛂࡉࡏࡓࠋ཯ᛂ⤊஢ᚋࠊษ∦ࢆPBS࡛Ὑίࡋࠊ஧ḟᢠయࢆᐊ
 ࡛5᫬㛫཯ᛂࡉࡏࡓࠋ஧ḟᢠయ࡜ࡋ࡚ࠊAlexa Fluor 488 ᢠࣛࣅࢵࢺIgGᢠయ (1:100; 
ThermoFisher)ࠊAlexa Fluor 594 ᢠ࣐࢘ࢫIgGᢠయ (1:100; ThermoFisher) ࡲࡓࡣ
Alexa Fluor 594 ᢠࣖࢠIgGᢠయ (1:100; ThermoFisher)ࢆ཯ᛂࡉࡏࡓࠋ཯ᛂ⤊஢ᚋࠊษ
∦ࢆPBS࡛ὙίࡋࠊVector® TrueVIEW Autofluorescence Quenching kit (Vector) ࢆ⏝
࠸࡚5ศ㛫ฎ⌮ࡍࡿࡇ࡜࡛⾑⌫⣔ࡢ⮬↛Ⓨගࢆ࣐ࢫ࢟ࣥࢢࡋࡓࠋ཯ᛂ⤊஢ᚋࠊษ∦ࢆPBS
࡛Ὑίࡋࠊ⣽⬊᰾ࢆDAPI solution (1:200; ྠோ໬Ꮫ◊✲ᡤ) ࢆ⏝࠸࡚ᑐẚᰁⰍࡋࡓࠋ཯
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ᛂ⤊஢ᚋࠊษ∦ࢆPBS࡛ὙίࡋࠊỈ⣔ᑒධ๣ (Fluoromount-G, Thermo Fisher) ࢆ⏝࠸
࡚ᑒධࡋࡓࠋࢧࣥࣉࣝࡢ⺯ගࢩࢢࢼࣝࢆඹ↔Ⅼ࣮ࣞࢨ࣮㢧ᚤ㙾 (Olympus FV1000D 




⏤᮶࠿࣍ࢫࢺ⣽⬊⏤᮶࠿ࢆ☜ㄆࡍࡿࡓࡵࣄࢺvimentinࡢ2㔜ᰁⰍࢆ⾜ࡗࡓࠋ⛣᳜ᚋ1, 2, 4, 
8 㐌┠ࡢ㢌⵹㦵ࢆᅇ཰ࡋࠊ4 % ࣃ࣒ࣛ࣍ࣝ࢔ࣝࢹࣄࢻ⁐ᾮ࡛ᅛᐃࡋࡓᚋࠊ30㸣 ࢫࢡ࣮ࣟ
ࢫ⁐ᾮ࡛⨨᥮ࡋࡓࠋࢧࣥࣉࣝࢆOCT ࢥࣥࣃ࢘ࣥࢻ (Sakura Finetek USA) ࡟ໟᇙᚋࠊࢡ
ࣛ࢖࢜ࢫࢱࢵࢺࢆ⏝࠸࡚ཌࡉ20 μm࡛ⷧษࡋ෾⤖ษ∦ࢆస〇ࡋࡓࠋ㦵෾⤖ษ∦ࢆPBS࡛Ὑ
ίᚋࠊ1᫬㛫㢼஝ࡉࡏࡓࠋ PBS࡛Ὑίᚋࠊ5 % BSA/0.1% TWEEN 20/PBS ⁐ᾮࢆ⏝࠸࡚
ᐊ ࡛1᫬㛫ࣈࣟࢵ࢟ࣥࢢࡋࡓࠋPBS࡛Ὑίᚋࠊ୍ḟᢠయ࡜ࡋ࡚ࠊᢠࣄࢺvimentin ࣛࣅࢵ
ࢺࣔࣀࢡ࣮ࣟࢼࣝᢠయ (SP20; 1:100; abcam) ࢆ4Υ୍࡛᫨ኪ཯ᛂࡉࡏࡓࠋ཯ᛂ⤊஢ᚋࠊษ
∦ࢆPBS࡛Ὑίࡋࠊ஧ḟᢠయ࡜ࡋ࡚Alexa Fluor 488 ᢠࣛࣅࢵࢺIgGᢠయ (1:100; 
ThermoFisher) ࡜ࠊAlexa 594 phalloidin (1:50; ThermoFisher) ࢆᐊ ࡛5᫬㛫཯ᛂࡉࡏ
ࡓࠋ཯ᛂ⤊஢ᚋࠊษ∦ࢆPBS࡛Ὑίࡋࠊ⣽⬊᰾ࢆDAPI solution (1:200; ྠோ໬Ꮫ◊✲ᡤ)
ࢆ⏝࠸࡚ᑐẚᰁⰍࡋࡓࠋ཯ᛂ⤊஢ᚋࠊษ∦ࢆPBS ࡛ὙίࡋࠊỈ⣔ᑒධ๣ (Fluoromount-
G, Thermo Fisher) ࢆ⏝࠸࡚ᑒධࡋࡓࠋࢧࣥࣉࣝࡢ⺯ගࢩࢢࢼࣝࢆඹ↔Ⅼ࣮ࣞࢨ࣮㢧ᚤ㙾 
(Olympus FV1000D laser scanning confocal microscope; ࢜ࣜࣥࣃࢫ) ࢆ⏝࠸࡚ほᐹࡋ
ࡓࠋࡉࡽ࡟ࠊ㦵⣽⬊ࢿࢵࢺ࣮࣡ࢡᵓ㐀ࢆྍど໬ࡍࡿࡓࡵࠊZ㍈࡟0.5 μmࡢཌࡉ࡛40ࢫࣛ࢖






➨ 3㡯 ⤖ ᯝ 
⛣᳜ 1 㐌㛫࠾ࡼࡧ 2 㐌㛫ᚋ࡛ࡣࠊḞᦆ㒊࡟࢔ࢽࣜࣥࣈ࣮ࣝ࡟㟷ࡃᰁⰍࡉࢀࡿᗂᙅ࡞ᇶ㉁
ࢆㄆࡵࠊࣄࢺ COLϨࡢᰁⰍീ࡜୍⮴ࡍࡿࡇ࡜࠿ࡽࠊ⛣᳜ࡋࡓ C-MSCs⏤᮶ࡢᇶ㉁࡛࠶ࡿࡇ
࡜ࡀ♧ࡉࢀࡓࠋ୍᪉࡛ࠊࡇࡢẁ㝵࡛ࡣ C-MSCsᵓ㐀ෆ㒊࡟ࣄࢺ OPNࠊࣄࢺ OCNࡢⓎ⌧ࡣ
☜ㄆࡉࢀ࡞࠿ࡗࡓ (ᅗ 4A)ࠋὀ┠ࡍ࡭ࡁࡇ࡜࡟ࠊ⛣᳜ 4㐌㛫ᚋ࡛ࡣࠊ୰ኸ㒊࡟ᙧᡂࡉࢀࡓ㦵
ᵝ⤌⧊ෆ㒊࡟࢔ࢰ࣑࢝ࣝࣥ Gࠊ࢜ࣞࣥࢪ G ࡟㉥ࡃᰁⰍࡉࢀࡿᐦ࡞ᇶ㉁ᵓ㐀ࢆㄆࡵࡿࡼ࠺࡟
࡞ࡾࠊ⛣᳜ 8㐌ᚋ࡟ࡣࡑࡢ⠊ᅖࡢᣑ኱ࡀほᐹࡉࢀࡓ (ᅗ 4A)୍ࠋ ᪉࡛୰ኸ㒊ࡢ㦵ᵝ⤌⧊ࢆそ
࠺ࡼ࠺࡟᩿➃㒊㎶⦕࠿ࡽᙧᡂࡉࢀࡓ㦵ᵝ⤌⧊ෆ㒊ࡣࠊḞᦆ㒊࿘ᅖ࡜ྠ⛬ᗘࡢᐦ࡞ᇶ㉁࡟ࡼ
ࡾᵓᡂࡉࢀ࡚࠸ࡓ (ᅗ 4A)ࠋࡲࡓࠊ⛣᳜ 4 㐌㛫ᚋ࠾ࡼࡧ 8 㐌㛫ᚋ࡟୰ኸ㒊࡟ᙧᡂࡉࢀࡓ㦵
ᵝ⤌⧊ෆ㒊࡟ࡣࠊࣄࢺ COLϨࠊࣄࢺ OCNࠊࣄࢺ OPNࡢỿ╔ࡀ☜ㄆࡉࢀࡓࡇ࡜࠿ࡽࠊࢻࢼ
࣮⣽⬊ࡀศἪࡋࡓ㦵ᇶ㉁㛵㐃ࢱࣥࣃࢡࡀ㦵෌⏕࡟ᐤ୚ࡋ࡚࠸ࡿࡇ࡜ࡀ♧ࡉࢀࡓ (ᅗ 4A)ࠋ௨


















➨ 3⠇ ⬺⣽⬊ฎ⌮ࢆ⾜ࡗࡓ C-MSCsࡢ㦵⤌⧊෌⏕⬟ࡢ᳨ウ 
 






➨ 2㡯 ᮦᩱ࡜᪉ἲ 
1. C-MSCsࡢ⬺⣽⬊ฎ⌮ἲ 
 C-MSCsࢆ㸫80Υ࡛෾⤖ࡋࡓᚋࠊᐊ ࡛ゎ෾ࡍࡿ᧯సࢆ 4ᅇ⧞ࡾ㏉ࡋࡓࠋࡑࡋ࡚ࠊ25 mM 
NH4OHỈ࡛ 1᫬㛫ฎ⌮ࡋࠊMilliQỈ࡛Ὑίࡍࡿࡇ࡜࡛⬺⣽⬊ฎ⌮ࢆ⾜ࡗࡓ [37]ࠋ௨ୗࠊ




 ➨ 2❶ ➨ 1⠇ ➨ 2㡯 4. 1) ࡟グ㍕ࡋࡓ᪉ἲ࡛⾜ࡗࡓࠋ 
 
2) ⺯ගච␿ᰁⰍ 





 ➨ 2❶ ➨ 1⠇ ➨ 2㡯 4. 2) ࡟グ㍕ࡋࡓ᪉ἲ࡛ࠊDecell-C-MSCsࡢ෾⤖ษ∦ࢆస〇ࡋ
ࡓࠋ෾⤖ษ∦ࢆ 1᫬㛫㢼஝ࡉࡏࠊPBS࡛Ὑίᚋࠊ5-FAM-conjugated Collagen 
Hybridizing Peptide (F-CHP) (3Helix, Inc., Salt Lake City, UT, USA) /PBS⁐ᾮࢆ 15 
μMࡢ⃰ᗘ࡛ 4Υࠊ୍᫨ኪ཯ᛂࡉࡏࡓࠋ཯ᛂ⤊஢ᚋࠊษ∦ࢆ PBS࡛ὙίࡋࠊỈ⣔ᑒධ๣ 
(Fluoromount-G; Thermo Fisher) ࢆ⏝࠸࡚ᑒධࡋࡓࠋࢧࣥࣉࣝࡢ⺯ගࢩࢢࢼࣝࢆඹ↔Ⅼ




3. SCID࣐࢘ࢫ㢌⵹ෙ 1.6mm㦵Ḟᦆࣔࢹࣝ࡬ࡢ Decell-C-MSCs⛣᳜ 
➨ 2❶ ➨ 2⠇ ➨ 2㡯 1. ࡟グ㍕ࡋࡓ᪉ἲ࡛ࠊDecell-C-MSCsࡢ⛣᳜ࢆ⾜ࡗࡓࠋ 
 
4. micro CT ゎᯒἲ  




 ➨ 2❶ ➨ 2⠇ ➨ 2㡯 3. ࡟グ㍕ࡋࡓ᪉ἲ࡛⾜ࡗࡓࠋ 
2) AzanᰁⰍ 
➨ 3❶ ➨ 2⠇ ➨ 2㡯 1. ࡟グ㍕ࡋࡓ᪉ἲ࡛⾜ࡗࡓࠋ 
3)⺯ගච␿ᰁⰍ 
➨ 3❶ ➨ 1⠇ ➨ 2㡯 1. ࡟グ㍕ࡋࡓ᪉ἲ࡛ࣄࢺ vimentin ࡢᰁⰍࢆ⾜࠸ࠊ➨ 3❶ ➨ 2





  ➨ 2❶ ➨ 2⠇ ➨ 2㡯 4. ࡟グ㍕ࡋࡓ᪉ἲ࡛⾜ࡗࡓࠋ 
 









ࡀ♧ࡉࢀࡓࠋḟ࡟ࠊDecell-C-MSCsࢆ SCID࣐࢘ࢫ㢌⵹ෙ㦵Ḟᦆ࡟⛣᳜ࡋࡓ (ᅗ 5B)ࠋ
micro CT᧜ᙳࢆ⾜ࡗࡓ࡜ࡇࢁࠊ⛣᳜ᚋ 8㐌ࡲ࡛⤒㐣ࡋ࡚ࡶḞᦆ㒊࡟▼⅊໬≀ࡢᙧᡂࡣ࡯
࡜ࢇ࡝ㄆࡵࡽࢀ࡞࠿ࡗࡓ (ᅗ 5C, D)ࠋ⤌⧊Ꮫⓗホ౯ࢆ⾜ࡗࡓ࡜ࡇࢁࠊ⛣᳜ 1㐌㛫ᚋ࡛ࡣḞ
ᦆ㒊࡟ Decell-C-MSCs⏤᮶࡜ᛮࢃࢀࡿࣄࢺ COLϨ㝧ᛶࡢᇶ㉁ᵓ㐀ࢆ☜ㄆࡋࡓࠋࡋ࠿ࡋࠊ
ࡑࡢᚋ࡟㦵⤌⧊ᙧᡂࡀㄏᑟࡉࢀࡿࡇ࡜ࡣ࡞ࡃࠊᇶ㉁ࡣ᫬㛫⤒㐣౫Ꮡⓗ࡟௦ㅰࡉࢀ࡚࠸ࡗࡓ 



































➨ 4❶ ⪃ ᐹ 
 


























ࣛ࢖ࣥᅉᏊࡀᚲせ࡛࠶ࡗࡓྍ⬟ᛶࢆ♧၀ࡍࡿࠋᐇ㝿ࠊbone morphogenetic protein (BMP) - 2
ࢆⓎ⌧ࡋࡓMSCsࡢ⛣᳜ࡀ࣐࢘ࢫ㦵ᢡࣔࢹࣝ࡟㦵⤌⧊෌⏕ࢆㄏᑟࡋࡓሗ࿌ࡀ࠶ࡿ [34, 
42]ࠋࡉࡽ࡟ࠊZhouࡽࡣ㦵ศ໬ㄏᑟᇵᆅ࡛ᇵ㣴ࡋࡓࣄࢺMSCsࢆ࣐࢘ࢫ㢌⵹ෙ㦵Ḟᦆࣔࢹ
















































































1) Xeno-free/Serum-free ᮲௳ୗ࡟సᡂࡋࡓ C-MSCsࡣࠊᚑ᮶ࡢ FBS౑⏝ୗ࡟స〇ࡋࡓ
C-MSCs࡜ྠᵝ࡟ࠊ㔜⠜࡞⣽⬊Ṛࢆㄆࡵࡎࠊ⣽⬊ࡢ㊊ሙ࡜࡞ࡿ㇏ᐩ࡞Ϩᆺࢥ࣮ࣛࢤࣥ࡟ࡼ
ࡗ࡚ᵓᡂࡉࢀ࡚࠸ࡓࠋ 
2) C-MSCsࡢ⛣᳜ࡣ SCID࣐࢘ࢫ㢌⵹ෙ㦵Ḟᦆࢆຠᯝⓗ࡟෌⏕ࡋࡓࠋ 
3) C-MSCsࡢ⛣᳜࡟ࡼࡿ㦵⤌⧊෌⏕ᶵᗎࡣࠊḞᦆ㒊࡟࠾ࡅࡿࢻࢼ࣮⣽⬊⮬㌟ࡢ㦵ศ໬࡜࣍
ࢫࢺ⣽⬊ࡢ㦵ᙧᡂㄏᑟಁ㐍࡟ࡼࡿࡶࡢ࡛࠶ࡿࡇ࡜ࡀ♧၀ࡉࢀࡓࠋ 
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ᅗ 1  Xeno-free/Serum-free᮲௳ୗ࡛ࡢ C-MSCsస〇ࠋ 
(A) C-MSCsࡢస〇㐣⛬ࡢᶍᘧᅗࢆ♧ࡍࠋa: Day0 (⣽⬊ࢩ࣮ࢺ) ࡢ⫗║ᡤぢࠋb: Day3 (C-
MSCs) ࡢ⫗║ᡤぢࠋ(B) Day0 (⣽⬊ࢩ࣮ࢺ) ࡛ࢧࣥࣉࣝࡢᅇ཰ࢆ⾜࠸ࠊࣇ࣮ࣟࢧ࢖ࢺ࣓ࢺ
࣮ࣜࢆ⏝࠸࡚MSC࣐࣮࣮࢝ࡢⓎ⌧ࢆほᐹࡋࡓࠋ㟷ࡶࡋࡃ㉥⥺ࡢࣄࢫࢺࢢ࣒ࣛࡣ CD105, 
CD90, CD73, CR45, ࡲࡓࡣ CD34㝧ᛶ⣽⬊ࢆ♧ࡍࠋ⅊Ⰽࡢࣄࢫࢺࢢ࣒ࣛࡣ࢔࢖ࢯࢱ࢖
ࣉ࣭ࢥࣥࢺ࣮ࣟࣝ IgGࢆ཯ᛂࡉࡏࡓ⣽⬊ࢆ♧ࡍࠋ(C) Day0, Day1, Day3࡛ C-MSCsࢆᅇ
཰ࡋࠊH&EᰁⰍࢆ⾜ࡗࡓࠋୖẁࡣᙅᣑ኱ീ (ࢫࢣ࣮ࣝࣂ࣮=500 μm)ࠊୗẁࡣᙉᣑ኱ീ 
(ࢫࢣ࣮ࣝࣂ࣮=50 μm) ࢆ♧ࡍࠋ(D&E) Day3࡛ C-MSCsࢆᅇ཰ࡋࠊᅛᐃᚋ࡟㐃⥆ษ∦ࢆ
స〇ࡋࠊᰁⰍࢆ⾜ࡗࡓࠋ(D) TUNELᰁⰍࡢ⤌⧊ീࠋ TUNEL㝧ᛶ⣽⬊ (⥳)ࠊ⣽⬊᰾ (㟷) 
(ࢫࢣ࣮ࣝࣂ࣮=50 μm)ࠋ (E) 㦵ᇶ㉁㛵㐃ࢱࣥࣃࢡࡢච␿ᰁⰍീࠋ ࣄࢺϨᆺࢥ࣮ࣛࢤࣥ 
(hCOLϨ) (⥳)ࠊࣄࢺ࢜ࢫࢸ࣏࢜ࣥࢳࣥ (hOPN) (㉥)ࠊࣄࢺ࢜ࢫࢸ࢜࢝ࣝࢩࣥ (hOCN) 





ᅗ 2 Xeno-free/Serum-free᮲௳ୗ࡛స〇ࡉࢀࡓ C-MSCsࡢ⛣᳜ࡣ࣐࢘ࢫ㢌⵹㦵ࢆ෌⏕ࡍ
ࡿࠋ 
(A) C-MSCs⛣᳜㐣⛬ࡢᶍᘧᅗࢆ♧ࡍࠋC-MSCsࢆேᕤ㊊ሙᮦᩱࢆ⏝࠸ࡎ࡟ࠊSCID࣐࢘
ࢫ㢌⵹ෙ 1.6 mmḞᦆ࡟⛣᳜ࡋࡓࠋࢥࣥࢺ࣮ࣟࣝ࡜ࡋ࡚㠀⛣᳜⩌ࢆタᐃࡋࡓࠋ(B) ⛣᳜ 1, 
2, 4, 8㐌㛫ᚋࡢmicro CT⏬ീࠋ(C) ⛣᳜ 1, 2, 4, 8㐌㛫ᚋࡢ㦵Ḟᦆ㒊࡟࠾ࡅࡿ෌⏕㦵㔞 











ᅗ 2 Xeno-free/Serum-free᮲௳ୗ࡛స〇ࡉࢀࡓ C-MSCsࡢ࣐࢘ࢫ㢌⵹ෙ㦵Ḟᦆ⛣᳜ᚋࡢ
⤌⧊ീࠋ 
(D&E) ⛣᳜ 1, 2, 4, 8㐌㛫ᚋ࡟࣐࢘ࢫࢆᒕẅࡋࠊ㢌⵹㦵ࢆᅇ཰ᚋ࡟ᅛᐃࡋࡓࠋ๓㢌᩿࡛ษ
∦ࢆస〇ࡋࠊH&EᰁⰍࢆ⾜ࡗࡓࠋ (D) ⛣᳜ 8㐌ᚋࡢ㠀⛣᳜⩌ (ࢫࢣ࣮ࣝࣂ࣮=500 μm)ࠋ
(E) ⛣᳜ 1, 2, 4, 8㐌ᚋࡢ C-MSCs⛣᳜⩌ (ࢫࢣ࣮ࣝࣂ࣮=500 μm)ࠋୗẁ࡟࣎ࢵࢡࢫ㡿ᇦ





ᅗ 3 C-MSCs⛣᳜㒊࡟࠾ࡅࡿ⛣᳜ࡉࢀࡓࢻࢼ࣮⣽⬊࡜࣍ࢫࢺ⣽⬊ࡢศᕸࠋ 
(A) ⛣᳜ 1, 2, 4, 8㐌㛫ᚋ࡟࣐࢘ࢫࢆᒕẅࡋࠊ㢌⵹㦵ࢆᅇ཰ᚋ࡟ᅛᐃࡋࡓࠋ๓㢌᩿࡛ษ∦ࢆ
స〇ࡋࠊࣄࢺ vimentin࡟ᑐࡍࡿ⺯ගච␿ᰁⰍࢆ⾜ࡗࡓࠋࣄࢺ vimentin (hVimentin) 
(⥳)ࠊ⣽⬊᰾ (㟷)ࠋୖẁࡣᙅᣑ኱ീ (ࢫࢣ࣮ࣝࣂ࣮=500 μm)ࠊୗẁࡣᙉᣑ኱ീ (ࢫࢣ࣮ࣝ
ࣂ࣮=50 μm) ࢆ♧ࡍࠋ(B) 㦵Ḟᦆ୰ኸ㒊ࠊ㎶⦕㒊 (୧ഃ)ࠊ୰㛫㒊 (୧ഃ)ࡢ 5࠿ᡤ࡟ࡘ࠸
࡚ࠊࣄࢺ vimentin㝧ᛶࢻࢼ࣮⣽⬊ᩘ࡜ࣄࢺ vimentin㝜ᛶ࣍ࢫࢺ⣽⬊ᩘࢆィ ࡋࡓࠋ⤖ᯝ









ᅗ 4  C-MSCs⛣᳜㒊࡟࠾ࡅࡿ㦵ᇶ㉁㛵㐃ࢱࣥࣃࢡࡢⓎ⌧ࠋ 
(A) ⛣᳜ 1, 2, 4, 8㐌㛫ᚋ࡟࣐࢘ࢫࢆᒕẅࡋࠊ㢌⵹㦵ࢆᅇ཰ᚋ࡟ᅛᐃࡋࡓࠋ๓㢌᩿࡛ษ∦ࢆ
స〇ࡋࠊAzanᰁⰍ࡜ࣄࢺ㦵ᇶ㉁㛵㐃ࢱࣥࣃࢡࡢච␿ᰁⰍࢆ⾜ࡗࡓࠋࣄࢺϨᆺࢥ࣮ࣛࢤࣥ 
(hCOLϨ) (⥳)ࠊࣄࢺ࢜ࢫࢸ࣏࢜ࣥࢳࣥ (hOPN) (㉥)ࠊࣄࢺ࢜ࢫࢸ࢜࢝ࣝࢩࣥ (hOCN) 
(㉥)ࠊ⣽⬊᰾ (㟷)ࠋୖẁࡣᙅᣑ኱ീ (ࢫࢣ࣮ࣝࣂ࣮=200 μm)ࠊୗẁࡣᙉᣑ኱ീ (ࢫࢣ࣮ࣝ










ᅗ 4  C-MSCs⛣᳜㒊࡟࠾ࡅࡿ㦵⣽⬊ᙧែゎᯒࠋ 
(B) ⛣᳜ 2㐌㛫ࡲࡓࡣ 4㐌㛫ᚋ࡟࣐࢘ࢫࢆᒕẅࡋࠊ㢌⵹㦵ࢆᅇ཰ᚋ࡟ᅛᐃࡋࡓࠋࢡࣛ࢖࢜
ࢫࢱࢵࢺࢆ⏝࠸࡚๓㢌᩿࡛෾⤖ษ∦ࢆస〇ࡋࠊࣄࢺ vimentin࡜ F-actinࡢᰁⰍࢆ⾜ࡗࡓࠋ
ࣄࢺ vimentin (hVimentin) (⥳)ࠊ F-actin (㉥)ࠊ⣽⬊᰾ (㟷)ࠋᕥ࡟ᙅᣑ኱ീ (ࢫࢣ࣮ࣝࣂ











ᅗ 5  Decell-C-MSCs⛣᳜㒊ࡢ⤌⧊ീࠋ 
(A) C-MSCsࠊDecell-C-MSCsࠊ⇕ฎ⌮࡟ࡼࡗ࡚ࢥ࣮ࣛࢤࣥࢆኚᛶࡉࡏࡓ C-MSCs (heat-
treated C-MSCs) ࢆ࠙ᮦᩱ࡜᪉ἲࠚ࡟ᚑ࠸స〇ࡋࡓࠋᅛᐃᚋ࡟ษ∦ࢆస〇ࡋࠊH&Eᰁ
ⰍࠊCOLϨࡢ⺯ගච␿ᰁⰍࠊ5-FAM conjugated-collagen hybridizing peptide࡟ࡼࡿᰁⰍ
ࢆ⾜ࡗࡓࠋᕥ࡟ᙅᣑ኱ീ (ࢫࢣ࣮ࣝࣂ࣮=200 μm)ࠊᕥ࠿ࡽ 2, 3, 4␒┠࡟࣎ࢵࢡࢫ㡿ᇦࡢᙉ










ᅗ 5  Decell-C-MSCsࡢ⛣᳜ࡣ࣐࢘ࢫ㢌⵹㦵ࢆ෌⏕ࡋ࡞࠿ࡗࡓࠋ 
(B) Decell-C-MSCs⛣᳜㐣⛬ࡢᶍᘧᅗࢆ♧ࡍࠋDecell-C-MSCsࢆேᕤ㊊ሙᮦᩱࢆ⏝࠸ࡎ
࡟ࠊSCID࣐࢘ࢫ㢌⵹ෙ 1.6mmḞᦆ࡟⛣᳜ࡋࡓࠋ(C) ⛣᳜ 1, 2, 4, 8㐌㛫ᚋࡢmicro CT⏬








ᅗ 5  Decell-C-MSCsࡢ࣐࢘ࢫ㢌⵹ෙ㦵Ḟᦆ⛣᳜ᚋࡢ⤌⧊ീࠋ 
(E) ⛣᳜ 1, 2, 4, 8㐌㛫ᚋ࡟࣐࢘ࢫࢆᒕẅࡋࠊ㢌⵹㦵ࢆᅇ཰ᚋ࡟ᅛᐃࡋࡓࠋ๓㢌᩿࡛ษ∦ࢆ
స〇ࡋࠊH&EᰁⰍࠊAzanᰁⰍࠊࣄࢺ vimentin࡜ࣄࢺ㦵ᇶ㉁㛵㐃ࢱࣥࣃࢡࡢ⺯ගච␿ᰁ
Ⰽࢆ⾜ࡗࡓࠋࣄࢺϨᆺࢥ࣮ࣛࢤࣥ (hCOLϨ) (⥳)ࠊࣄࢺ࢜ࢫࢸ࣏࢜ࣥࢳࣥ (hOPN) (㉥)ࠊ
ࣄࢺ࢜ࢫࢸ࢜࢝ࣝࢩࣥ (hOCN) (㉥)ࠊ⣽⬊᰾ (㟷)ࠋୖẁࡣᙅᣑ኱ീ (ࢫࢣ࣮ࣝࣂ࣮=200 
μm)ࠊୗẁࡣ࣎ࢵࢡࢫ㡿ᇦࡢᙉᣑ኱ീ (ࢫࢣ࣮ࣝࣂ࣮= 50 μm) ࢆ♧ࡍࠋⓑ࣎ࢵࢡࢫࡣ㦵Ḟ
ᦆ㒊࡟࠾ࡅࡿ hCOLϨࡢ඲యീࢆ♧ࡍࠋ 
 
 
